My GLP-1 weight loss slowed down. Is it not working?

It is almost certainly still working. A stall after several months on a GLP-1 is a documented, expected phase of treatment, not medication failure. Your body has adapted to carrying less weight, and the deficit that drove the early loss has narrowed until it closed.

What counts as a GLP-1 plateau?

Not two weeks. Not three.

Weight moves day to day on water, sodium, hormones, digestion and sleep, and a short flat stretch is noise. Clinically, a plateau means roughly eight to twelve weeks with little or no change in weight. Anything shorter is fluctuation, and treating it as a crisis is how people talk themselves out of a plan that was working.

The first honest answer is often that it has not been long enough to know yet.

When do GLP-1 plateaus usually happen?

Later than most people expect, and on a predictable curve. Loss is fastest early — during initiation and dose escalation — then slows, then levels off.

In the STEP 5 trial of semaglutide, which followed participants for two years, the weight-loss curve fell steeply through roughly week 60 and then flattened. It stayed flat: mean loss was about 15 percent at week 104, essentially unchanged from the point where it levelled off.

Sit with what that curve actually shows. The plateau in that trial was not the end of the results. It wasthe result — the weight stayed off, on continued treatment, for another year.

Why did my weight loss stop on semaglutide or tirzepatide?

Because you are a smaller person now, and a smaller person needs less fuel.

This is metabolic adaptation, and it is among the best-documented findings in obesity research. Rosenbaum and Leibel, writing in the International Journal of Obesity, described the coordinated metabolic, hormonal and autonomic responses that follow weight loss and act to defend the weight you started at. Movement gets cheaper too — the same flight of stairs costs less when you are hauling less mass up it.

At the same time, appetite regulation pushes back. The hunger signals that quietened down early start pushing again. A GLP-1 blunts that push. It does not delete it.

The deficit that drove your first thirty pounds narrows until intake and expenditure meet. That meeting point is the plateau.

Is the medication still doing anything if the scale isn’t moving?

Yes, and this is the misconception that causes the most damage.

A GLP-1 continues to regulate appetite and blood glucose during a plateau. What changed is not the drug’s activity — it is the size of the gap between what you eat and what you burn.

Which is why stopping at a plateau is the expensive move. In the STEP 1 trial extension, participants who came off semaglutide regained about two-thirds of the weight they had lost within a year: a mean loss of 17.3 percent on treatment had become 5.6 percent a year after withdrawal. A plateau means the weight is being held. Stopping is what gives it back.

Should I increase my dose to break a plateau?

That is not a question this article can answer, and you should be suspicious of any fitness brand that tries.

Dose changes, switching agents, and continuing versus stopping are clinical decisions that belong to you and your prescriber. What we can do is tell you what to bring to that appointment so it is actually useful.

What actually changes the picture?

Three things consistently matter, and most people are not doing them.

Resistance training.Rapid weight loss takes muscle and bone with it if nothing pulls the other way, and clinical guidance around GLP-1 therapy increasingly emphasises resistance training and adequate protein specifically to protect lean mass. Muscle is metabolically active tissue — losing it deepens the adaptation. This is the highest-leverage change available to you, and the one a prescription cannot do for you.

Protein, honestly measured. Appetite suppression makes it very easy to fall well short without noticing. People on GLP-1s frequently undereat protein and overeat nothing at all, which sounds fine and is not.

Sleep and stress. Both move hunger. Neither appears on a food log. A stall that arrived alongside three months of bad sleep is not a mystery.

What should I tell my doctor about a plateau?

Walk in with data instead of a feeling. Bring:

• How long the scale has actually been flat, in weeks, with the numbers
• Whether any doses were missed, late, or stored improperly
• What your protein intake looks like across a normal week
• Whether you are doing any resistance training, and how often
• Non-scale changes: measurements, how clothes fit, energy, sleep, recent labs

That list turns “it stopped working” into a clinical conversation your prescriber can act on.

What AION does with a stall

AION is the coach inside Sculpt, and a plateau is the situation he is built for — because it is a data problem before it is a motivation problem. We wrote a whole piece on that.

When a member’s record names a GLP-1, his coaching rules change. He will not stack a calorie deficit on top of an already-suppressed appetite, he holds the protein floor, and he treats muscle preservation as the priority rather than a nice-to-have. That is not a tone adjustment — it is a different set of instructions he is given before he answers you.

He also holds the whole picture rather than one number: training, food, measurements, and check-ins that ask you to rate energy, sleep, stress, hunger, performance and adherence — precisely the inputs a plateau tends to hide behind.

And here is what he will not do, deliberately: he does not diagnose, does not comment on your dose, and never tells anyone to start, stop or change a medication. Those go back to the person who wrote the prescription. That boundary is built into what he is allowed to say, not appended to the bottom of the screen.